EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 9

Pau d'arco Handroanthus impetiginosus (Mart. ex DC.) Mattos

Also called: lapacho, taheebo, red lapacho, Tabebuia impetiginosa (synonym), Tabebuia avellanedae (synonym)

Pau d'arco, also called lapacho or taheebo, is the inner bark of Handroanthus (formerly Tabebuia) trees, traditionally taken as a decoction. Its naphthoquinones lapachol and beta-lapachone are the most studied constituents; human data are limited.

Category
Botanical
Part used
Inner bark
Strongest evidence
C Limited
Native range
Native from central Mexico to southern tropical America (POWO: "Central Mexico to S. Tropical America")
Reviewed
2026-10-29

Class 3 Limited studies in people. No randomized trial of pau d'arco alone was found. The only human study of pau d'arco alone found was a single-arm, open-label trial in 12 women (1,050 mg/day encapsulated bark for 8 weeks). [2]

Fact-checked 2026-10-29 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

4 topics studied2 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Pau d'arco does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Pau d'arco, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Period pain (primary dysmenorrhea)CA single-arm, open-label trial in 12 women (1,050 mg/day encapsulated bark for 8 weeks) reported lower pain intensity than at baseline; with no control group, the result is preliminary. [2]
Oral mucositis during head and neck radiotherapyCA phase II study without a control group gave 40 patients a lapacho-based oral solution during radiotherapy: 27.5% developed grade 2 and 10% grade 3 mucositis, and none stopped radiotherapy because of it. [3]
Isolated lapachol in chronic myelocytic leukemiaCMSK reports that lapachol, a compound in pau d'arco, did not show clinical improvement in patients with chronic myelocytic leukemia. [1]
Antibacterial, antifungal and antitumor activityDThese activities were seen in laboratory and animal studies; MSK states they have not been shown in humans. [1]

Main constituents: Lapachol and beta-lapachone (naphthoquinones), thought to be the active constituents [1]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • 1,050 mg/day of encapsulated Tabebuia avellanedae for 8 weeks (single-arm safety and tolerability trial). [2]
  • A lapacho-based oral solution taken 3 times a day from the first to the last day of radiotherapy (phase II study). [3]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Lapachol showed fetotoxic effects in animal studies.

    1 statement in the profile.

    Details and sources
  • Interactions with medicines
    1 listed

    Anticoagulant and antiplatelet drugs

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    None on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • Lapachol inhibits vitamin K epoxide and quinone reductases, an action similar to warfarin; MSK lists use with anticoagulant or antiplatelet drugs as a reason not to take pau d'arco because bleeding risk may increase (clinical relevance not known). [1]
  • A clinical study reported nausea, vomiting and urine discoloration. [1]
  • In animal studies, large chronic doses of lapachol caused anemia; lapachol also showed reproductive toxicity, fetotoxic effects and chromosomal abnormalities. [1]
  • In the 8-week dysmenorrhea trial, 9 of 12 women reported an adverse event, mostly mild; none was an FDA serious adverse event, and 9 of 12 completed the study. [2]
Interactions

Interactions

Known interactions of Pau d'arco
WithWhat happens
Anticoagulant and antiplatelet drugsPau d'arco may increase their activity and the risk of bleeding; clinical relevance is not known. [1]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • Red lapacho on international markets appears to vary in quality and composition, which makes product claims hard to assess; reviewers called for appropriate analytical quality control. [4]
Regulation

Regulatory status

  • US: FDA states that, by law, it does not approve dietary supplements or their labeling before they are marketed; firms are responsible for the safety and labeling of their products. [7]
  • US: No NDI notification naming pau d'arco (Handroanthus or Tabebuia, lapacho, taheebo) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [8]
  • International trade: Handroanthus species are listed in CITES Appendix II (in effect since 25 November 2024); the listing annotation covers logs, sawn wood, veneer sheets, plywood and transformed wood. [9]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Lapachol Naphthoquinone [P1]
  • beta-Lapachone Naphthoquinone [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • No NDI notification naming pau d'arco (Handroanthus or Tabebuia, lapacho, taheebo) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of pau d'arco (Handroanthus or Tabebuia bark) or lapachol was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]
  • NTP technical reports list checked 2026-10-29: no report on pau d'arco or lapachol found. [P4]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • Anticoagulant and antiplatelet drugs: Pau d'arco may increase their activity; lapachol inhibits vitamin K epoxide and quinone reductases, similar to warfarin. Clinical relevance is not known. [P1]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • A 2009 review (Gómez Castellanos et al.) found that red lapacho material on international markets seems to vary in quality and composition, and reviewed the analytical techniques needed to control it. [P5]

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test of the dietary ingredient (at least one appropriate test or examination before use) — 21 CFR 111.75(a)(1)(i) requires identity verification of every component that is a dietary ingredient, unless FDA exempts the firm on petition under 111.75(a)(1)(ii). [P6]
  • Botanical identity and chemical profile of the bark by validated analytical techniques — Material on international markets varies in quality and composition (Gómez Castellanos et al. 2009). [P5]

Supply and conservation

  • IUCN Red List: Near Threatened (NT), via GBIF species API, retrieved 2026-10-29. [P7]
  • CITES Appendix II: Handroanthus spp. listed at CoP19 (November 2022), in effect since 25 November 2024, annotation #17: logs, sawn wood, veneer sheets, plywood and transformed wood. [P8]

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • Lapachol showed fetotoxic effects in animal studies. [P1]

Sources for this profile

  1. Memorial Sloan Kettering Cancer Center. About Herbs: Pau d'Arco (last updated April 13, 2023), 2023-04-13. mskcc.org
  2. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  3. IARC Monographs. Agents classified by the IARC Monographs (list of classifications, checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
  4. National Toxicology Program. Technical Reports (list checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
  5. Gómez Castellanos JR, Prieto JM, Heinrich M. Red Lapacho (Tabebuia impetiginosa) - a global ethnopharmacological commodity? J Ethnopharmacol 2009;121(1):1-13 (PMID 18992801), 2009-01-12. pubmed.ncbi.nlm.nih.gov
  6. eCFR. 21 CFR 111.75 (current as of October 27, 2026), 2026-10-27. ecfr.gov
  7. GBIF species API: IUCN Red List category for Handroanthus impetiginosus, 2026-10-29. api.gbif.org
  8. UNEP-WCMC / CITES Secretariat. Species+: Handroanthus impetiginosus, CITES listing (retrieved 2026-10-29), 2026-10-29. speciesplus.net
Sources

Sources

  1. Memorial Sloan Kettering Cancer Center. About Herbs: Pau d'Arco (last updated April 13, 2023), 2023-04-13. mskcc.org
  2. McClure C, et al. Safety and tolerability of Pau d' Arco (Tabebuia avellanedae) for primary dysmenorrhea: a single-arm, open-label trial on adults ages 18-45. Adv Integr Med 2022;9(3):159-166 (PMID 36960315), 2022-09. pubmed.ncbi.nlm.nih.gov
  3. Giacomelli I, et al. Oral lapacho-based medication: an easy, safe, and feasible support to prevent and/or reduce oral mucositis during radiotherapy for head and neck cancer. Nutr Cancer 2015;67(8):1247-53 (PMID 26451712), 2015. pubmed.ncbi.nlm.nih.gov
  4. Gómez Castellanos JR, Prieto JM, Heinrich M. Red Lapacho (Tabebuia impetiginosa) - a global ethnopharmacological commodity? J Ethnopharmacol 2009;121(1):1-13 (PMID 18992801), 2009-01-12. pubmed.ncbi.nlm.nih.gov
  5. Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data (Govaerts et al., Sci Data 2021). Handroanthus impetiginosus (Mart. ex DC.) Mattos (accessed 2026-10-29; Kew cannot warrant the accuracy of the data), 2026-10-29. powo.science.kew.org
  6. World Checklist of Vascular Plants (WCVP), Darwin Core archive, GBIF dataset f382f0ce-323a-4091-bb9f-add557f3a9a2 (published 2026-06-04): synonym records, 2026-06-04. gbif.org
  7. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
  8. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  9. UNEP-WCMC / CITES Secretariat. Species+: Handroanthus impetiginosus, CITES listing (retrieved 2026-10-29), 2026-10-29. speciesplus.net
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.